Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone mineral density and DMPA.

Carolyn Westhoff1

  • 1Department of Obstetrics and Gynecology, Columbia University, 630 West 168th Street, New York, NY 10032, USA.

The Journal of Reproductive Medicine
|October 17, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial.

Contraception·2026
Same author

The International Contraceptive Access Foundation's model for improving access to the hormonal intrauterine device.

Contraception·2025
Same author

Emergency contraception for individuals weighing 80 kg or greater: A randomized trial of 30 mg ulipristal acetate and 1.5 mg or 3.0 mg levonorgestrel.

Contraception·2024
Same author

Advancing diversity, equity, inclusion, and anti-racism in Contraception: A statement of commitment from the Editorial Board.

Contraception·2023
Same author

Intradepartmental redeployment of faculty and staff.

Seminars in perinatology·2020
Same author

Acceptability of the Woman's Condom in a phase III multicenter open-label study.

Contraception·2019

Depot medroxyprogesterone acetate (DMPA) may cause a slight bone density decrease, but this is reversible and does not lead to clinical issues. DMPA remains an effective contraceptive option when considering risks and benefits.

Area of Science:

  • Endocrinology
  • Reproductive Health
  • Bone Metabolism

Background:

  • The association between depot medroxyprogesterone acetate (DMPA) and bone mineral density (BMD) changes is debated.
  • Numerous studies have investigated this potential link and its clinical significance.

Purpose of the Study:

  • To evaluate the relationship between DMPA use and changes in bone mineral density.
  • To assess the clinical relevance of any observed BMD alterations.

Main Methods:

  • Review of prospective studies examining DMPA's effect on bone density.
  • Analysis of clinical outcomes associated with DMPA use and BMD changes.

Main Results:

  • Most prospective studies indicate a modest decline in BMD with DMPA use.

Related Experiment Videos

  • Some studies have not confirmed this association.
  • No clinical consequences have been documented, and any BMD loss appears reversible.

    • Conclusions:

    • DMPA-associated bone density loss, if it occurs, is reversible and unlikely to cause adverse clinical events.
    • The efficacy of DMPA for pregnancy prevention should be weighed against potential BMD changes in a risk-benefit assessment.